E N D
2. Causal agent for Influenza Virus: genetic material wrapped in a membrane
Three major groups of influenza
Influenza C
Influenza B
Influenza A
Subdivided into several subtypes (H5N1, …)
Infect not only humans but also animals
Mutate more rapidly
Influenza C: mild disease
Influenza B: sporadic outbreaks of more severe respiratory disease
Influenza A: greatest concernInfluenza C: mild disease
Influenza B: sporadic outbreaks of more severe respiratory disease
Influenza A: greatest concern
3.
4. Evolution of the Influenza virus The virus is in constant evolution
Two types of evolution
Antigenic Drift:
Small errors in transcription that are not corrected
Antigenic Shift
Mutation
Recombination
6. Different aspects of Influenza
Seasonal influenza
Avian influenza : animal disease
Human cases of avian influenza
Pandemic influenza
7. Seasonal Influenza Seasonal fluctuation of the number of cases
Certain degree of immunity in the population
Mortality principally in certain well defined risk groups (e.g. elderly, people with chronic diseases…)
Vaccination is possible: composition needs to be adapted every season
8. Avian Influenza and human cases of AI Veterinary problem
Virus H1 to H15, N1 to N9
Pathogenicity is very variable
Low pathogenic AI
Highly pathogenic AI
Very high mortality
Transmission
Very contagious in animals , little or no immunity
Transmission to humans is very rare ( very close contact)
No transmission between humans
9. Pandemic Influenza Antigenic shift
Inter human transmission
No Immunity in the population
New strain of the influenza virus
Can infect a big proportion of the population
Mortality Rate: unknown
No vaccine available
10. INFLUBELInfluenza epidemic modelling andscenario analysis software Modelling of influenza epidemics
Study of distribution over time of morbidity, health care utilization, and mortality
Scenario analysis to study the influence of vaccination, antivirals, and social distancing measures Marc Van RanstMarc Van Ranst
11. Influbel parameters Population
Basic reproduction number
Seeding parameters
Social interaction – Social distancing
Symptomatic/asymptomatic infections
Morbidity parameters
GP use and hospitalisation parameters
Vaccination and antiviral use parameters
13. International collaboration WHO
Surveillance of human cases of avian influenza
Follow up of the viral genome
Composition of the seasonal flu vaccine
Follow up of the phases
14. International collaboration EISS
Weekly surveillance report for 29 countries
Operates the Community Network of Reference Laboratories for Human Influenza in Europe
15. International collaboration ECDC core activities
Surveillance
Scientific advice
Identification of emerging health threats (“epidemic intelligence”)
Training
Communications
Providing technical assistance (“country support”)